Intelligence » Celiac Disease » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

A Promising Celiac Disease Drug is Moving into Phase II Clinical Trial

Saturday, November 18, 2017 -- ImmusanT, a biotechnology company focusing on protecting patients with celiac disease against the effects of gluten, has announced that it has secured $40 million in funding to advance its drug, Nexvax2®, into a Phase II clinical trial. Nexvax2 is a therapeutic vaccine designed to stimulate immune tolerance in patients with celiac disease. Nexvax2® is the […]